OMNIAB INC
OABINASDAQTrading Snapshot
- Day Range
- β
- 52-Week Range
- $1.35 β $5.45
- Volume (shares)
- β
- Avg Volume (shares)
- β
- Shares Outstanding
- 145.9M
- Next Earnings
- 2027-03-02
Fundamentals Snapshot
- Annual Revenue
- $19M
- Last Q Revenue
- $4M
- P/E Ratio
- β
- P/S Ratio
- 18.2x
- EPS (TTM)
- $-0.34
- Dividend Yield
- β
- Dilution (1yr)
- +21.9%
OMNIAB INC
OABIAbout OMNIAB INC
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates
News unavailable.